Variations in Cardiovascular Disease Risk Factor Prevalence Among London Adults: Insights from the TOGETHER Study - Takeaways - MDSpire

Variations in Cardiovascular Disease Risk Factor Prevalence Among London Adults: Insights from the TOGETHER Study

  • By

  • Fotios Barkas

  • Malo Dirou

  • Kanika I. Dharmayat

  • Mahsa Mazidi

  • Antonio J. Vallejo-Vaz

  • Christophe A. T. Stevens

  • Amany Elshorbagy

  • Kausik K. Ray

  • March 3, 2026

  • 0 min

Share

  • 1

    Cardiovascular disease (CVD) is the leading cause of mortality in the UK, accounting for 26% of all deaths annually.

  • 2

    Premature CVD-related deaths disproportionately affect South Asian and Black ethnic groups, with over 48,000 deaths before age 75.

  • 3

    The TOGETHER study aims to assess CVD risk factors among ethnically diverse adults aged 30-90 in London, addressing gaps in public health strategies.

  • 4

    Data for the study was collected from primary care electronic health records, focusing on demographics, smoking status, and various health metrics.

  • 5

    Traditional CVD risk factors do not fully explain ethnic disparities, indicating a need for tailored prevention strategies beyond population-level approaches.

Original Source(s)

Variations in Cardiovascular Disease Risk Factor Prevalence Among London Adults: Insights from the TOGETHER Study

  • by Fotios Barkas, Malo Dirou, Kanika I. Dharmayat, Mahsa Mazidi, Antonio J. Vallejo-Vaz, Christophe A. T. Stevens, Amany Elshorbagy, Kausik K. Ray

  • March 3, 2026

Related Content

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Serum uric acid levels and cardiorenal complication prevalence in hypertensive patients before and after the COVID-19 pandemic: a retrospective cross-sectional study from a tertiary traditional Chinese medicine hospital

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.